Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00397319 · ClinicalTrials.gov registry record
Growth Hormone's Effect on the Cardiovascular System
A clinical trial, sponsored by Vanderbilt University.
- Terminated
- Registry status
- 26
- Enrollment target
NCT00397319: Clinical Trial study, sponsored by Vanderbilt University.
NCT00397319 is a clinical trial that was terminated before completion, run by Vanderbilt University. The registered enrollment target is 26 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00397319 was terminated before completion, sponsored by Vanderbilt University.
- TERMINATED
- Registry status
- 26 participants
- Enrollment target
Study Summary
To evaluate specific markers of cardiovascular risk before and after growth hormone replacement therapy in a population of growth hormone deficient adults, as compared to an age, gender, and BMI-matched healthy population.
Interventions
- DRUG Growth Hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2005-08 |
| Est. Completion | 2006-12 |
Why NCT00397319 stopped before completion
NCT00397319 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 26 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which Growth Hormone is the first listed.
NCT00397319 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00397319 about?
NCT00397319 is a clinical study titled "Growth Hormone's Effect on the Cardiovascular System". To evaluate specific markers of cardiovascular risk before and after growth hormone replacement therapy in a population of growth hormone deficient adults, as compared to an age, gender, and BMI-matched healthy population.
What is the current status of trial NCT00397319?
This trial is currently terminated. The enrollment target is 26 participants. The study started on 2005-08. Estimated completion is 2006-12.
What interventions are being tested in trial NCT00397319?
The interventions under investigation include: Growth Hormone (DRUG).
Who is sponsoring clinical trial NCT00397319?
This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia